Insmed Competitive Intelligence & Landscape

Insmed (insmed.com) is a people-first global biopharmaceutical company dedicated to transforming the lives of patients facing serious and rare diseases [insmed.com/company/]. Founded in 1988, with its headquarters located at 700 US Highway 202/206, Bridgewater, NJ 08807 [investor.insmed.com/faq], the company emphasizes a culture of open minds and collaboration, actively involving patients and families in their decision-making processes [insmed.com/].

Insmed's core mission revolves around delivering first- and best-in-class therapies guided by science and collective expertise [insmed.com/company/]. They focus on understanding real-world challenges to develop meaningful solutions for patients [insmed.com/company/]. Their commitment is encapsulated in the phrase "For us, everything starts with people" [insmed.com/].

The company's product portfolio includes ARIKAYCE® (amikacin liposome inhalation suspension), their first commercial product, approved in the US, Europe, and Japan [insmed.com/annual_report/2023/Insmed_2023_AnnualReport.pdf]. They also feature BRINSUPRI® (Brensocatib) within their respiratory therapeutic area pipeline, and investigational products such as INS1033 for immunology & inflammation, and INS201, a gene therapy, for neuro & other rare therapeutic areas [insmed.com/science/product-portfolio-pipeline/].

Insmed operates with a "we're in" commitment, signifying their dedication to championing culture, prioritizing patients, and pursuing science without boundaries [insmed.com/]. This commitment extends to their operational philosophy, where they strive to advance science sustainably and ethically, covering aspects like innovation delivery, people empowerment, community strengthening, and planet protection [insmed.com/]. While the company's size isn't explicitly stated with a numerical figure, its global operations and diverse product pipeline suggest a significant enterprise in the biopharmaceutical sector.

Insmed develops and commercializes therapies for serious and rare diseases, with a focus on ARIKAYCE® and BRINSUPRI® [https://insmed.com/therapies/].

ARIKAYCE® (amikacin liposome inhalation suspension) is one of their key therapies, while BRINSUPRI® (brensocatib) has recently received U.S. FDA approval for the treatment of non-cystic fibrosis bronchiectasis (NCFB) [https://annualreport.insmed.com/].

For BRINSUPRI™ (brensocatib), the Wholesale Acquisition Cost (WAC) price is listed as $88,000.00 annually for both the 25 mg and 10 mg tablets [https://insmed.com/state-disclosures/CO-and-CT-Price-Disclosure-Form-72525v5.pdf]. It's important to note that patients' out-of-pocket costs may vary from this WAC price. There are no generic prescription drugs listed as comparable alternatives to BRINSUPRI™ in the provided pricing disclosures.

Insmed offers patient support programs designed to facilitate access to their medicines. The inLighten® Patient Support program provides educational resources and other assistance to eligible patients throughout their treatment journey [https://insmed.com/patients/patient-access/]. For investigational therapies or unapproved products, Insmed also provides potential managed access pathways, which can include Compassionate Use, Post-Trial Access, and Named Patient Programs [https://insmed.com/patients/patient-access/access-to-investigational-or-unapproved-therapies/]. These programs are designed to help patients in need access medical products that are still under investigation or not yet commercially available in their country [https://insmed.com/wp-content/uploads/2022/07/Insmed-EAP-July-2022.pdf].

Insmed (insmed.com) actively recruits across a broad spectrum of roles, signaling a strategic focus on expanding its biopharmaceutical endeavors. The company's careers portal (careers.insmed.com) showcases opportunities in critical areas such as Research & Development, Commercial, Drug Development & Medical Affairs, and Enabling Functions [careers.insmed.com/job-search/]. This sustained hiring trend underscores Insmed's commitment to delivering breakthroughs for patients with serious and rare diseases.

Recent job postings indicate a demand for specialized talent. Examples include a Director, Talent & Workforce Strategy (R3428) [careers.insmed.com/posting/director-talent-workforce-strategy/R3428/] and a Senior Manager, Channel Management (R3373) [careers.insmed.com/posting/senior-manager-channel-management/R3373/], which would support the compliant and efficient movement of pharmaceutical products. The company also seeks a Director, Downstream Process Development and Manufacturing Biologics (R3525) [careers.insmed.com/posting/director-downstream-process-development-and-manufacturing-biologics/R3525/], a Director, Program Management (R3314) [careers.insmed.com/posting/director-program-management/R3314/], and a Senior Director, Clinical Research & Development (R3141) [careers.insmed.com/posting/senior-director-clinical-research-development/R3141/]. These roles highlight an investment in both scientific innovation and operational excellence.

Further reinforcing its growth trajectory, Insmed is hiring for positions such as Sr Director, Medical Affairs - Respiratory (R3326) [careers.insmed.com/posting/sr-director-medical-affairs---respiratory/R3326/] and Manager, Quality Control (R3470) [careers.insmed.com/posting/manager-quality-control/R3470/]. The company emphasizes a culture where “every moment and every patient counts,” and values every person’s contributions to meaningful progress [careers.insmed.com/posting/director-program-management/R3314/]. There is no indication of recent layoffs; rather, the consistent posting of diverse roles across various departments suggests a period of sustained growth and expansion in its global biopharmaceutical operations.

Insmed (insmed.com) has demonstrated significant financial growth, with total company revenues reaching $606.4 million for the full year 2025 [https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update]. This growth is further evidenced by a strong first quarter in 2026, where total revenues hit $306.0 million [https://investor.insmed.com/2026-05-07-Insmed-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update]. The company's key therapies, ARIKAYCE® and BRINSUPRI®, are major revenue drivers. ARIKAYCE® generated $433.8 million for the full year 2025 [https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update], and BRINSUPRI® contributed $172.7 million in 2025, with an impressive $144.6 million in the fourth quarter alone [https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update].

Looking ahead, Insmed projects robust growth for its products, expecting BRINSUPRI® revenues to be at least $1 billion for the full year 2026 and reiterating ARIKAYCE® revenue guidance of $450 million to $470 million for the same period [https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update]. This positive outlook is supported by strong quarterly performances, with BRINSUPRI® revenues of $207.9 million in the first quarter of 2026, marking a 44% growth over the previous quarter [https://investor.insmed.com/2026-05-07-Insmed-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update]. ARIKAYCE® also saw $98.1 million in revenue for the first quarter of 2026, growing 6% over the prior year's first quarter [https://investor.insmed.com/2026-05-07-Insmed-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update].

In terms of fundraising and financial maneuvers, Insmed successfully priced an underwritten public offering of 7,812,500 shares of its common stock at $96.00 per share on June 11, 2025. This offering generated gross proceeds of $750 million for the company [https://investor.insmed.com/2025-06-11-Insmed-Announces-Pricing-of-750-Million-Public-Offering-of-Common-Stock]. This capital infusion underscores investor confidence and supports the company's aggressive growth trajectory. The company's valuation has seen substantial appreciation, growing from $4 billion to more than eight times that amount in the two years leading up to 2025 [https://annualreport.insmed.com/].

Insmed is listed on NASDAQ under the ticker symbol INSM [https://investor.insmed.com/sec].

Insmed (insmed.com) actively participates in various investor and scientific conferences to share updates on its pipeline and financial performance. For instance, in May 2026, Insmed management was scheduled to present at the BofA Securities 2026 Healthcare Conference and the RBC Capital Markets Global Healthcare Conference investor.insmed.com/2026-04-30-Insmed-to-Present-at-May-2026-Investor-Conferences, following an appearance at the 46th Annual TD Cowen Healthcare conference in March 2026 investor.insmed.com/2026-02-13-Insmed-To-Present-at-March-2026-Investor-Conferences. The company also has a consistent presence at major industry events such as the Goldman Sachs Annual Global Healthcare Conference, with participation confirmed for the 47th annual event in June 2026 investor.insmed.com/2026-05-27-Insmed-to-Present-at-the-2026-Goldman-Sachs-Annual-Global-Healthcare-Conference. These engagements provide platforms for Insmed to connect with the investment community.

Insmed also makes significant contributions to scientific discourse by presenting data at key medical conferences. In May 2026, Insmed was set to present data across its respiratory portfolio, including late-breaking ARIKAYCE® results from its Phase 3b ENCORE Study, at the American Thoracic Society International Conference investor.insmed.com/2026-05-04-Insmed-to-Present-Data-Across-Its-Respiratory-Portfolio,-Including-Late-Breaking-ARIKAYCE-R-Results-from-Phase-3b-ENCORE-Study,-at-the-American-Thoracic-Society-International-Conference-2026. Earlier, in June 2025, the company shared topline results from its Phase 2b study of TPIP in PAH investor.insmed.com/events?item=143, underscoring its commitment to advancing its scientific portfolio.

Beyond major conferences, Insmed also engages through webinars. For example, a commercial webinar was held in June 2024, providing further opportunities for stakeholders to learn about the company's initiatives investor.insmed.com/events?item=120. These diverse event participations highlight Insmed's dedication to transparent communication with both investors and the scientific community.